An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Lymphoid Leukemia | Non-Hodgkin's Lymphoma | Phase I
What is the purpose of this trial?
This study is designed to evaluate the safety and pharmacokinetics of BTCT4465A when administered as a single agent by intravenous (IV) infusion to participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
- Trial withGenentech, Inc.
- Start Date04/26/2022
- End Date10/31/2020
- Last Updated04/28/2022
- Study HIC#1509016491